1-2 of 2
Peter Senter
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with 90Y or 177Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy

Linda Mårtensson, Zhongmin Wang, Rune Nilsson, Tomas Ohlsson, Peter Senter, Hans-Olov Sjögren, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7104s–7108s.
https://doi.org/10.1158/1078-0432.CCR-1004-0004
Published: 03 October 2005
View article titled, Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with <sup>90</sup>Y or <sup>177</sup>Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy
Open the PDF for Determining Maximal Tolerable Dose of the Monoclonal Antibody BR96 Labeled with <sup>90</sup>Y or <sup>177</sup>Lu in Rats: Establishment of a Syngeneic Tumor Model to Evaluate Means to Improve Radioimmunotherapy in another window
Journal Articles

Targeted Delivery in Primary and Metastatic Brain Tumors: Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium

Nancy D. Doolittle, Lauren E. Abrey, Nicolay Ferrari, Walter A. Hall, Edward R. Laws, Roger E. McLendon, Leslie L. Muldoon, David Peereboom, Darryl R. Peterson, C. Patrick Reynolds, Peter Senter, Edward A. Neuwelt
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (6): 1702–1709.
Published: 01 June 2002
View article titled, Targeted Delivery in Primary and Metastatic Brain Tumors: <subtitle>Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium</subtitle>
Open the PDF for Targeted Delivery in Primary and Metastatic Brain Tumors: <subtitle>Summary Report of the Seventh Annual Meeting of the Blood-Brain Barrier Disruption Consortium</subtitle> in another window